Interferon in relapsing-remitting multiple sclerosis
57 results
1 - 57
Interferon in relapsing‐remitting multiple sclerosis
Interferon in relapsing-remitting multiple sclerosis - Interferons‐beta versus glatiramer acetate for relapsing‐remitting multiple sclerosis
- alemtuzumab versus interferon beta 1a for relapsing‐remitting multiple sclerosis
Alemtuzumab more effective than interferon for multiple sclerosis- Mycophenolate mofetil for relapsing-remitting multiple sclerosis: Cochrane systematic review
- Daclizumab for relapsing remitting multiple sclerosis
- Multiple sclerosis (MS)
- Statins for multiple sclerosis
- Alemtuzumab for multiple sclerosis
- Natalizumab for relapsing remitting multiple sclerosis
- Immunomodulators and immunosuppressants for progressive multiple sclerosis: a network meta‐analysis
- Fingolimod for relapsing‐remitting multiple sclerosis
- Azathioprine for people with multiple sclerosis
- Interferon beta for secondary progressive multiple sclerosis
- Immunomodulators and immunosuppressants for relapsing‐remitting multiple sclerosis: a network meta‐analysis
- Fingolimod for relapsing-remitting multiple sclerosis
- Ocrelizumab for multiple sclerosis
- Interferon Beta for Primary Progressive Multiple Sclerosis
- Recombinant interferon beta or glatiramer acetate for delaying conversion of the first demyelinating event to multiple sclerosis
- Interferon beta for secondary progressive multiple sclerosis
- Statins for multiple sclerosis: Cochrane systematic review
- Alemtuzumab for multiple sclerosis
- Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis (RRMS): a network meta-analysis
- Rituximab for relapsing-remitting multiple sclerosis: Cochrane systematic review
- Natalizumab for relapsing remitting multiple sclerosis
- Immunomodulators and immunosuppressants for multiple sclerosis: a network meta‐analysis
- Laquinimod for multiple sclerosis: Cochrane systematic review
- Teriflunomide for multiple sclerosis
- Dimethyl fumarate for multiple sclerosis: Cochrane systematic review
- Adverse effects of immunotherapies for multiple sclerosis: a network meta‐analysis
- Natalizumab for multiple sclerosis